Rituximab treatment of myasthenia gravis: a systematic review
R Tandan, MK Hehir, W Waheed, DB Howard - Muscle & nerve, 2017 - Wiley Online Library
Rituximab is a chimeric mouse/human anti‐CD20 monoclonal immunoglobulin. We
reviewed the efficacy and safety of rituximab in 169 myasthenia gravis (MG) patients from …
reviewed the efficacy and safety of rituximab in 169 myasthenia gravis (MG) patients from …
History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy
PJB Dyck, JA Tracy - Mayo Clinic Proceedings, 2018 - Elsevier
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is probably the best
recognized progressive immune-mediated peripheral neuropathy. It is characterized by a …
recognized progressive immune-mediated peripheral neuropathy. It is characterized by a …
Morvan syndrome: clinical and serological observations in 29 cases
Objective: A study was undertaken to describe the clinical spectrum, voltage‐gated
potassium channel (VGKC) complex antibody specificities, and central nervous system …
potassium channel (VGKC) complex antibody specificities, and central nervous system …
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
Myasthenia gravis is an autoimmune disorder of the neuromuscular junction caused by
circulating antibodies specif ic for the post-synaptic acetylcholine receptor or, in a minority of …
circulating antibodies specif ic for the post-synaptic acetylcholine receptor or, in a minority of …
Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease
characterized by neurological symptoms and signs of progressive weakness, paresthesias …
characterized by neurological symptoms and signs of progressive weakness, paresthesias …
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
M Mahdi‐Rogers, R Brassington… - Cochrane Database …, 2017 - cochranelibrary.com
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a
disease that causes progressive or relapsing and remitting weakness and numbness. It is …
disease that causes progressive or relapsing and remitting weakness and numbness. It is …
[HTML][HTML] Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): protocol for a double-blind, randomized, placebo-controlled …
S Shimizu, M Iijima, Y Fukami, N Tamura… - JMIR Research …, 2020 - researchprotocols.org
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an
immune-mediated peripheral neuropathy that is currently classified into several clinical …
immune-mediated peripheral neuropathy that is currently classified into several clinical …
An update on the management of chronic inflammatory demyelinating polyneuropathy
KC Gorson - Therapeutic advances in neurological disorders, 2012 - journals.sagepub.com
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated
disorder of the peripheral nervous system with clinical features that include weakness …
disorder of the peripheral nervous system with clinical features that include weakness …
Overlooked non-motor symptoms in myasthenia gravis
S Suzuki, K Utsugisawa, N Suzuki - Journal of Neurology …, 2013 - jnnp.bmj.com
Patients with myasthenia gravis (MG) may have various non-motor symptoms in addition to
fatigability and weakness of skeletal muscles. Thymomas contain abundant immature …
fatigability and weakness of skeletal muscles. Thymomas contain abundant immature …
[HTML][HTML] Autoimmune encephalitis—new awareness, challenging questions
The field of autoimmune encephalopathies has expanded rapidly in the last few years. It is
now well-established that a substantial proportion of encephalitides are associated with …
now well-established that a substantial proportion of encephalitides are associated with …